



Advocating with FDA

Austin Noll
MPS Society Annual Meeting
September 30, 2010

FDA Advocacy Opportunity

FDA held first public hearing on rare diseases in June

Purpose: Gain perspectives on various aspects of the development of medical products for the diagnosis, treatment or management of rare diseases

Meeting open to everyone

I attended and testified on behalf of the MPS Society

Meeting Participants

- **Patients / family members**
- **National Organization for Rare Disorders (NORD)**
- **Industry**
- **Dr. Kakkis' EveryLife Foundation**
- **Other Patient Societies**

Our Message to FDA

- **Need group dedicated to rare disease review**
 - Reviewers that understand genetics
- **Need ability to use reasonable biomarkers in studies**
 - In many situations, such as when there is CNS and bone involvement, clinical outcomes are very difficult to measure
- **Need more appropriate study designs**
 - No double-blinded, randomized studies with placebo controls
 - Sample sizes that reflect the rarity of these conditions
 - Inclusion criteria reflecting heterogeneity of population

Takeaways from Meeting

- **Requests coming from the patient societies and from industry were all very similar**
- **Glad to see FDA formally recognizing that issues exist with the process**
- **Concerned with how long it may take FDA to act**

Must Continue to Push for Reform

How can you help?



Policy with Partners - PwP

The Path to the Future



National MPS Society

Ask Me About
PwP



Policy with Partners

Support for Families. Research for a Cure.



PwP - What is It?



- A program designed to allow society members and others to *easily advocate for MPS*
- Contact your elected officials via pre-made faxes, emails
- Potential chance to visit D.C. personally to share your views

Help us get the word out



PwP Wants You





National
MPS
Society

Support for Families. Research for a Cure.

Thank You